Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 2/20 | 0.88 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.88 |
| ▸ | MEN1 | O00255 | 1/20 | 0.88 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.88 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.88 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 11/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5426026 | 1.00 | PDE4A (0.88) | PDE4APDE4DMEN1CHRM1KMT2A | |
| SCHEMBL7434908 | 1.00 | PDE4A (0.88) | PDE4APDE4DMEN1CHRM1KMT2A | |
| SCHEMBL5424919 | 1.00 | PDE4A (0.88) | PDE4APDE4DMEN1CHRM1KMT2A | |
| Levotofisopam SCHEMBL5431173 | 0.94 | KMT2A (1.00) | PDE4APDE4DMEN1CHRM1KMT2A | |
| Tofisopam SCHEMBL4585183 | 0.94 | KMT2A (1.00) | PDE4APDE4DMEN1CHRM1KMT2A | |
| Dextofisopam SCHEMBL29376877 | 0.94 | KMT2A (1.00) | PDE4APDE4DMEN1CHRM1KMT2A | |
| Tofisopam SCHEMBL43522 | 0.94 | KMT2A (1.00) | PDE4APDE4DMEN1CHRM1KMT2A | |
| Tofisopam SCHEMBL8086894 | 0.94 | KMT2A (1.00) | PDE4APDE4DMEN1CHRM1KMT2A | |
| Tofisopam SCHEMBL29832594 | 0.94 | KMT2A (1.00) | PDE4APDE4DMEN1CHRM1KMT2A | |
| Dextofisopam SCHEMBL236796 | 0.94 | KMT2A (1.00) | PDE4APDE4DMEN1CHRM1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161628-A1 | Phosphodiesterase inhibitors | GREENPHARMA (FR) | 2007-07-12 | — | — | US | claimed |
| US-8748172-B2 | Cell modeling of heme deficiency using ferrochelatase mutations | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-06-10 | — | — | US | disclosed |
| US-20140087447-A1 | Cell Modeling of Heme Deficiency using Ferrochelatase Mutations | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-03-27 | — | — | US | disclosed |
| US-8586530-B2 | Modulation of inhibition of ferrochelatase by N-methyl protoporphyrin | UNIVERSITY OF SOUTH FLORIDA (US) | 2013-11-19 | — | — | US | disclosed |
| US-20070254350-A1 | Modulation of Inhibition of Ferrochelatase by N-Methyl Protoporphyrin | UNIVERSITY OF SOUTH FLORIDA (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070161628-A1 | Phosphodiesterase inhibitors | GREENPHARMA (FR) | 2007-07-12 | — | — | US | disclosed |
| US-20050090428-A1 | Porphyrins with virucidal activity | EMORY UNIVERSITY (US) | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090428-A1 | Porphyrins with virucidal activity | ZP1, MAVS, VIP | PDE4A 4108/4885PDE4D 4014/4885MEN1 2332/4885 |
| US-20070161628-A1 | Phosphodiesterase inhibitors | PDE5A, PDE3A, PDE3B | PDE4A 6/4885PDE4D 12/4885MEN1 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.